Sai Life Sciences Limited (SAILIFE) — Announcement | 7 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Q1 FY27 revenue rises 12% YoY to ₹554 crores
🔄 What Changed
Revenue growth accelerated to 12% YoY; CRO grew 24% YoY; CMC pipeline strengthened with 33 active commercial molecules
🔮 What's Next
15-20% revenue growth target for FY27
💡 Investor Takeaway
The company is executing on its long-term growth strategy with strong operational momentum and pipeline visibility.

Sai Life Sciences reported Q1 FY27 revenue of ₹554 crores, up 12% YoY, driven by 24% growth in CRO and 33 active commercial molecules in CMC. The company highlighted strong pipeline visibility and continued investment in capacity expansion, including a new R&D facility and peptide platform development. Forward guidance reaffirms 15-20% revenue growth target for FY27.

📄 View Original Announcement (PDF)

About Sai Life Sciences Limited (SAILIFE)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹32,244.12 Cr P/E: 88.5 ROE: 14.6% ROCE: 20.1%

View full SAILIFE stock details →

📡 Get AI alerts when SAILIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SAILIFE — Free

📊 More SAILIFE filings

See all SAILIFE filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SAILIFE files new disclosures

Track SAILIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SAILIFE — Free

Free account · 2 AI queries/day